Breaking News, Financial News

Financial Report: Johnson & Johnson

FY Earnings hit by after-tax charges of $4.2 billion

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 4Q Revenues: $16.3 billion (+4%) 4Q Earnings: $218 million (-89%) FY Revenues: $65.0 billion (+6%) FY Earnings: $9.7 million (-28%) Comments: Worldwide Pharmaceutical sales were $24.4 billion for the year (+9%). Domestic sales declined 1%, while international sales were up 21%. Sales in the U.S. were negatively impacted by generic competition for Levaquin. Remicade sales for the year were $5.5 billion, up 19% in the wake of J&J’s new marketing agreement with Merck....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters